BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

327 related articles for article (PubMed ID: 9934343)

  • 21. Prostate specific antigen changes as related to the initial prostate specific antigen: data from the prostate, lung, colorectal and ovarian cancer screening trial.
    Crawford ED; Pinsky PF; Chia D; Kramer BS; Fagerstrom RM; Andriole G; Reding D; Gelmann EP; Levin DL; Gohagan JK
    J Urol; 2006 Apr; 175(4):1286-90; discussion 1290. PubMed ID: 16515981
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Prostate-Specific Antigen (PSA)-Based Population Screening for Prostate Cancer: An Economic Analysis.
    Tawfik A
    Ont Health Technol Assess Ser; 2015; 15(11):1-37. PubMed ID: 26366237
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Prostate-specific antigen velocity at low prostate-specific antigen levels as screening tool for prostate cancer: results of second screening round of ERSPC (ROTTERDAM).
    Roobol MJ; Kranse R; de Koning HJ; Schröder FH
    Urology; 2004 Feb; 63(2):309-13; discussion 313-5. PubMed ID: 14972478
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Specificity of serum prostate-specific antigen determination in the Finnish prostate cancer screening trial.
    Määttänen L; Hakama M; Tammela TL; Ruutu M; Ala-Opas M; Juusela H; Martikainen P; Stenman UH; Auvinen A
    Br J Cancer; 2007 Jan; 96(1):56-60. PubMed ID: 17213825
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Evidence of prostate cancer screening in a UK region.
    Gavin A; McCarron P; Middleton RJ; Savage G; Catney D; O'Reilly D; Keane PF; Murray LJ
    BJU Int; 2004 Apr; 93(6):730-4. PubMed ID: 15049981
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Prostate cancer mortality in relation to screening by prostate-specific antigen testing and digital rectal examination: a population-based study in middle-aged men.
    Agalliu I; Weiss NS; Lin DW; Stanford JL
    Cancer Causes Control; 2007 Nov; 18(9):931-7. PubMed ID: 17641982
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Prostate specific antigen: a role of PSA in the diagnosis of prostate cancer].
    Nutahara K; Higashihara E
    Rinsho Byori; 2001 Oct; 49(10):963-6. PubMed ID: 11769472
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Detection of prostate cancer: the impact of the European Randomized Study of Screening for Prostate Cancer (ERSPC).
    Schröder FH
    Can J Urol; 2005 Feb; 12 Suppl 1():2-6; discussion 92-3. PubMed ID: 15780157
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The distribution of serum prostate-specific antigen levels among American men: implications for prostate cancer prevalence and screening.
    Porter MP; Stanford JL; Lange PH
    Prostate; 2006 Jul; 66(10):1044-51. PubMed ID: 16598738
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Adherence to an annual PSA screening program over 3 years for brothers and sons of men with prostate cancer.
    Roumier X; Azzouzi R; Valéri A; Guillemin F; Fournier G; Cussenot O; Mangin P; Cormier L
    Eur Urol; 2004 Mar; 45(3):280-5; author reply 285-6. PubMed ID: 15036671
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Mass screening for prostate cancer is the best approach to early diagnosis and treatment of prostate cancer].
    Zhao XJ; Kong XB; Wang WH
    Zhonghua Nan Ke Xue; 2003 Nov; 9(8):563-5, 568. PubMed ID: 14689882
    [TBL] [Abstract][Full Text] [Related]  

  • 32. An evaluation of prostate-specific antigen as a screening test for prostate cancer.
    Dorr VJ; Williamson SK; Stephens RL
    Arch Intern Med; 1993 Nov; 153(22):2529-37. PubMed ID: 7694555
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Prostate-specific antigen: a review of the validation of the most commonly used cancer biomarker.
    Hernández J; Thompson IM
    Cancer; 2004 Sep; 101(5):894-904. PubMed ID: 15329895
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Prostate cancer screening strategies with re-screening interval determined by individual baseline prostate-specific antigen values are cost-effective.
    Kobayashi T; Goto R; Ito K; Mitsumori K
    Eur J Surg Oncol; 2007 Aug; 33(6):783-9. PubMed ID: 17408910
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Prostate cancer: a review of common underwriting problems, Part 1.
    Richie RC; Swanson JO
    J Insur Med; 2004; 36(3):242-54. PubMed ID: 15495440
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Screening for prostate cancer: updated experience from the Tyrol study.
    Horninger W; Berger A; Pelzer A; Klocker H; Oberaigner W; Schönitzer D; Severi G; Robertson C; Boyle P; Bartsch G
    Can J Urol; 2005 Feb; 12 Suppl 1():7-13; discussion 92-3. PubMed ID: 15780158
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The relationship between prostate cancer knowledge and beliefs and intentions to attend PSA screening among at-risk men.
    Hevey D; Pertl M; Thomas K; Maher L; Chuinneagáin SN; Craig A
    Patient Educ Couns; 2009 Feb; 74(2):244-9. PubMed ID: 18848753
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Changes in baseline PSA levels in Japanese men from 1988 to 2003.
    Ohi M; Ito K; Yamamoto T; Miyakubo M; Takechi H; Kubota Y; Suzuki K
    Urology; 2008 Jul; 72(1):95-8. PubMed ID: 18455775
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Behavioral associations between prostate and colon cancer screening.
    Carlos RC; Underwood W; Fendrick AM; Bernstein SJ
    J Am Coll Surg; 2005 Feb; 200(2):216-23. PubMed ID: 15664097
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Prostate-specific antigen assay using whole blood samples spotted on filter paper and its application to mass screening for prostate cancer.
    Nanri M; Nanri K; Fujiyama C; Tokuda Y; Nakamura K; Uozumi J
    Int J Urol; 2007 Jun; 14(6):505-9. PubMed ID: 17593094
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 17.